Now showing items 1-5 of 5
Recent Trends in Brand-Name and Generic Drug Competition
(Journal of Medical Economics, 2013)
Updated trends in US brand-name and generic drug competition
(Journal of Medical Economics, 2016-09)
Data Exclusivity for Biologics
(Nature Reviews Drug Discovery, 2011-01)
Implementation of the Biosimilar Pathway: Economic and Policy Issues
(Seton Hall Law Review, 2011)
Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.
(Health Aff (Millwood), 2011-11)
The evolution of pharmaceutical competition since Congress passed the Hatch-Waxman Act in 1984 raises questions about whether the act's intended balance of incentives for cost savings and continued innovation has been achieved. ...